Related Experiment Video
Updated: Nov 8, 2025
Comparative in vivo Study of gp96 Adjuvanticity in the Frog Xenopus laevis
Published on: September 16, 2010
Antineoplastic Effects and Mechanisms of a New RGD Chimeric Peptide from Bullfrog Skin on the Proliferation and
Xuan Jiang1, Xin Zhang1, Chao Fu1
1Tianjin Key Laboratory of Agricultural Animal Breeding and Healthy Husbandry, College of Animal Science and Veterinary Medicine, Tianjin Agricultural University, Tianjin, 300384, China.
Abstract:
Malignant melanoma, an increasingly common form of skin cancer, poses a significant threat to public health, especially when the disease progresses past skin lesions to the stage of advanced metastasis. In this work, a new anti-tumor peptide, temporin La (T-La), was selected from a cDNA library generated from bullfrog skin. Two new derivative antitumor peptides, T-La (S) and T-La (FS), were designed by bioinformatics analysis and coupled with the RGD small molecule peptide to create chimeric RGD peptides, (RGD-T-La [S] and RGD-T-La [FS]). Preliminary experiments showed that the new antitumor peptides had significant antitumor effects. After coupling to the chimeric RGD peptide, the targeted treatment of mouse melanoma was significantly improved. Our data demonstrate that the 4 peptides tested herein significantly inhibited the proliferation, migration, and invasion of B16F10 cells; with an increase in polypeptide concentration, the proportion of melanoma cells in the G0/G1 phase decreased or increased significantly, respectively, the reactive oxygen species (ROS) content increased significantly, the mitochondrial membrane potential decreased significantly, and the expression of pro-apoptotic Bax, Caspase-3, and Caspase-9 increased, and anti-apoptotic Bcl-2 decreased significantly. Tyr and MITF genes were significantly downregulated. In conclusion, the use of these new anti-tumor peptides, when combined with a chimeric RGD peptide, may increase ROS levels and decrease mitochondrial membrane potential by inhibiting the activity of mitochondria, thus releasing apoptosis-promoting factors in B16F10 cells. The present study describes a new potential strategy for the application of promising peptides in the treatment of various cancers.
Insights
New anti-tumor peptides, temporin La derivatives and RGD-coupled versions, effectively target melanoma. These peptides inhibit cancer cell growth and migration by inducing apoptosis through increased reactive oxygen species and decreased mitochondrial potential.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Malignant melanoma is a growing public health concern, particularly in its metastatic stages.
- Novel therapeutic strategies are needed to combat advanced skin cancer.
Purpose of the Study:
- To investigate the anti-tumor effects of novel temporin La (T-La) derived peptides.
- To evaluate the efficacy of chimeric RGD-T-La peptides in targeting melanoma.
Main Methods:
- Selection and design of T-La, T-La (S), T-La (FS), RGD-T-La (S), and RGD-T-La (FS) peptides.
- In vitro assessment of peptide effects on B16F10 melanoma cells, including proliferation, migration, invasion, cell cycle, ROS levels, mitochondrial membrane potential, and apoptosis markers.
- Analysis of key gene expression (Tyr, MITF).
Main Results:
- All four tested peptides significantly inhibited melanoma cell proliferation, migration, and invasion.
- Peptides induced apoptosis by increasing reactive oxygen species (ROS) and decreasing mitochondrial membrane potential.
- Upregulation of pro-apoptotic genes (Bax, Caspase-3, Caspase-9) and downregulation of anti-apoptotic Bcl-2 were observed.
- Downregulation of Tyr and MITF genes was significant.
Conclusions:
- Chimeric RGD-T-La peptides demonstrate enhanced targeted treatment of mouse melanoma.
- These peptides represent a promising new strategy for cancer therapy by inducing apoptosis via mitochondrial dysfunction.
- The findings suggest potential applications in treating various cancers.
